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Abstract
Background: Tumor hypoxia is linked to poor prognosis, but identification and quantification of tissue hypoxia
remains a challenge. The hypoxia-specificity of HIF-1a target genes in vivo has been questioned due to the
confounding influence of other microenvironmental abnormalities known to affect gene expression (e.g., low pH).
Here we describe a new technique that by exploiting intratumoral oxygenation heterogeneity allows us to identify
and objectively rank the most robust mRNA hypoxia biomarkers.
Methods: Mice carrying human (FaDudd) or murine (SCCVII) tumors were injected with the PET hypoxia tracer
FAZA. Four hours post-injection tumors were removed, frozen, and crushed into milligram-sized fragments, which
were transferred individually to pre-weighed tubes containing RNAlater and then weighed. For each fragment
radioactivity per tissue mass and expression patterns of selected mRNA biomarkers were analyzed and compared.
Results: In both tumour models, fragmentation into pieces weighing 10 to 60 mg resulted in tissue fragments
with highly variable relative content of hypoxic cells as evidenced by an up to 13-fold variation in FAZA
radioactivity per mass of tissue. Linear regression analysis comparing FAZA retention with patterns of gene
expression in individual tissue fragments revealed that CA9, GLUT1 and LOX mRNA levels were equally and
strongly correlated to hypoxic extent in FaDudd. The same link between hypoxia and gene expression profile was
observed for CA9 and GLUT1, but not LOX, in SCCVII tumors. Apparent in vivo hypoxia-specificity for other putative
molecular markers of tissue hypoxia was considerably weaker.
Conclusions: The portrayed technique allows multiple pairwise measurements of mRNA transcript levels and
extent of hypoxia in individual tumors at a smallest possible volumetric scale which (by limiting averaging effects
inherent to whole-tumor analysis) strengthen the conclusiveness on true hypoxia-specificity of candidate genes
while limiting the required number of tumors. Among tested genes, our study identified CA9, GLUT1 and possibly
LOX as highly specific biomarkers of tumor hypoxia in vivo.
Background
It is well known that tumor hypoxia limits the efficacy
of anticancer treatment and promotes tumor progres-
sion [1,2]. But the demonstration and quantification of
t i s s u eh y p o x i a ,w h i c hi sap r e r e q u i s i t ef o re f f e c t i v ea n d
adequate treatment, remains problematic especially in
clinical settings. Several studies have demonstrated that
direct measurement of physically dissolved oxygen with
tissue-invasive polarographic oxygen electrodes is able
to accurately separate patients into different risk cate-
gories [3,4]. However, most tumors are inaccessible to
the electrode without prior surgery and the method is
technically demanding which prevents its routine use in
clinical settings [5,6]. Clinically, more attractive methods
include non-invasive imaging of hypoxia-selective fluori-
nated nitroimidazoles developed for positron emission
tomography (PET) and blood oxygenation level depen-
dent (BOLD) MRI, but these techniques are expensive
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techniques see [7]). Histopathological evaluation of
needle tumor biopsies remains the gold standard for
definitive diagnosis of many cancers. More thorough
gene-expression analysis of the same tissue samples
may provide indirect knowledge on the tumor
microenvironment.
Since the discovery of the transcription factor
hypoxia-inducible factor 1a (HIF-1a), which orches-
trates cellular adaptation to hypoxia (for a recent review
see reference [8]), a huge effort has been made to iden-
tify HIF-1a regulated genes that are useful as hypoxia
biomarkers. Although the expression of HIF-1a and its
target genes are tightly regulated by pO2 under certain
well-defined in vitro conditions, the situation is more
complex in vivo. In accordance, it has been shown that
oxygen electrode data correlate poorly with the tissue
expression of putative hypoxia responsive genes assessed
in biopsies. In addition, studies examining the extent of
spatial overlap between exogenous administered hypoxia
probes (e.g., pimonidazole) and endogenous protein
markers in tumor sections have produced conflicting
results (for thorough reviews see references [9-11]).
Whether this relates to the confounding influence of
other microenvironmental parameters known to affect
gene expression (e.g., low pH and low glucose), fluctuat-
ing tumor oxygenation, sampling errors caused by intra-
tumoral heterogeneity or interlaboratory methodological
variation is unclear. Further studies that assess the spe-
cificity and heterogeneity of distribution of putative
endogenous markers of hypoxia in vivo are thus war-
ranted. Here we describe a new technique that by
exploiting intratumoral oxygenation heterogeneity allows
us to identify and rank in vivo hypoxia-responsive
mRNA biomarkers.
Methods
Subcutaneous flank tumors, established by injection of
murine SCCVII or human FaDudd squamous cell carci-
noma cells into C3H/HenTaC or NMRI-nu/nu female
mice, respectively, were used for experiments. The
SCCVII cell line was a gift from Dr. D. Siemann (Uni-
versity of Florida, Gainesville, Florida.) whereas FaDudd
was a gift from Dr. Michael Baumann (Department of
Radiation Oncology, Carl Gustav Carus University Hos-
pital and Medical Faculty, Dresden, Germany). The
study was performed in accordance with the national
legislation and approved by the Danish Animal Experi-
ments Inspectorate (Permission number: 2005/561-
1015).
When tumors reached a size of 500 to 1000 mm
3, non-
anaesthetized mice were injected with ~10 MBq of the
PET hypoxia tracer
18F-fluoroazomycin arabinoside
(FAZA) and returned to their cages. FAZA was allowed to
distribute for 4 hours before tumors were removed; this
time period ensures excellent hypoxia-specificity as shown
in previous studies [12,13]. Subsequently, excised tumors
were frozen. A piece of the thigh muscle was also collected
to determine tracer background contamination (unbound
tracer) in well-oxygenated tissue. Frozen tumors were
placed in a dry-ice cooled aluminium box and crushed
with a pair of pliers into milligram-sized fragments.
Twelve to 20 appropriately sized fragments were collected
from each tumor and transferred individually to pre-
weighed tubes containing 100 μl of RNAlater solution
(Qiagen), which prevents RNA degradation when samples
thaw. Tubes were then weighed and radioactivity in each
tumor fragment and a piece of weighed muscle was mea-
sured using a Packard well counter. Subsequently, tissue
fragments were homogenized in 300 μl RLT buffer (Qia-
gen) containing 10 ml/l b-mercaptoethanol using a Tissue-
Lyser (Qiagen) and totRNA was extracted using the
RNeasy mini kit (Qiagen) according to the manufactures
instructions. Total RNA (2 μg) was reverse transcribed
using random hexamer primers, and the High Capacity
Archive kit (Applied Biosystems) according to the manu-
factures instructions. The relative levels of the following
transcripts were measured by qPCR using Taqman
Gene Expression assays (ABI): CA9 (human assay:
Hs00154208_m1, mouse assay: Mm00519870_m1),
GLUT1 (human assay: Custom Taqman Gene Expression
assay, mouse assay: Mm01192270_m1), LOX (human
assay: Hs00184700_m1, mouse assay: Mm00495386_m1
and Mm00495384_m1), LDHA (human assay:
Hs00855332_g1, mouse assay: Mm00495282_g1),
GAPDH: (human assay: Hs00266705_g1, mouse assay:
Mm99999915_g1), ATF4 (human assay: Hs00909569_g1,
Mouse assay: Mm00515324_m2). For each reaction cDNA
(corresponding to 6 ng RNA), 1× assay mix and 1× Taq-
man Universal PCR mastermix (ABI) in a total of 15 μl
was mixed. All reactions were performed in duplicate.
Reactions were performed on an ABI Prism 7900 HT fast
Real-Time PCR system (ABI). Results were normalised to
three control genes: signal peptidase complex subunit 2
(SPCS2, human assay: Hs01585256_g1, mouse assay:
Mm00651159_m1), ribosomal protein L37a (RPL37A,
Human assay: forward primer TGT GGT TCC TGC ATG
AAG ACA reverse primer GTG ACA GCG GAA GTG
GTA TTG TAC probe 5TG GCT GGC GGT GCC TGG
A, mouse assay: Mm01546394_s1) and Nedd4 family inter-
acting protein 1 (NDFIP1, human assay: Hs00228968_m1,
mouse assay Mm0128333_m1) which were selected on the
basis of a previous microarray study [14], and the geN-
ORM Visual Basic application available in RealTime Stat-
miner (Intergromics). Data analysis was performed using
the RealTime Statminer software (Intergromics), which
calculates the geometric mean of the three control genes,
and the Comparative CT method.
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Page 2 of 9Finally, for each tumor fragment normalized mRNA
transcript levels of individual genes were compared to
relative FAZA retention (counts per weight of fragment/
counts per weight of muscle) and results displayed as
scatterplots on a per-tumor basis. The spatial link
b e t w e e ng e n ee x p r e s s i o na n dF A Z Aw a sa n a l y z e du s i n g
linear regression and Pearson’s correlation coefficients.
Results
A prerequisite for the usefulness of the technique por-
trayed in the present work is that the erratic tumor frag-
mentation results in fragments that differ widely in their
relative content of hypoxia, as quantified by relative
FAZA retention. This requirement was met since frag-
mentation into pieces weighing 10 to 60 mg resulted in
an up to 13-fold and 6-fold variation in radioactivity per
mass of tissue in FaDudd and SCCVII tumors, respec-
tively. Among a selection of well-known HIF-1a regu-
lated genes CA9 and GLUT1 were highly significantly
correlated to relative FAZA retention with nearly identi-
cal Pearson correlation coefficients (representative
examples are given in Figure 1 and 2 and all results are
summarized in Table 1), suggesting high hypoxia-
specificity in vivo. LOX mRNA expression displayed a
species difference with a strong positive correlation
between fold-induction and hypoxic extent in the
human tumor model (Figure 1 Table 1) and no or a
weak inverse relationship in the murine tumor model
(Figure 2 Table 1). Because of this unexpected tumor-
type dependent difference in expression pattern of LOX,
the results in SCCVII tumors were confirmed with an
independent assay for LOX, which align in a different
region of the transcript. The two assays generated
remarkably similar results (additional file 1 figure S1).
LDH transcript levels were also elevated in hypoxic tis-
sue fragments (Figure 3 and 4, Table 1) but in the mur-
ine tumor model the spatial link was significantly
weaker than for CA9 and GLUT1. GAPDH mRNA
levels were positively and significantly correlated to
FAZA retention in the murine tumor (Figure 4 Table 1),
whereas no clear association was observed in the xeno-
graft (Figure 3 Table 1). We also analyzed the link
between FAZA and the transcription factor ATF4,
which has previously been shown to be anoxia-induced
in a HIF-1a-independent manner [15]. The linkage
between ATF4 expression level and FAZA retention was
weak to modest with substantial tumor-to-tumor varia-
bility, but the positive correlation in SCCVII tumors was
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Figure 1 Relative expression of mRNA levels as a function of FAZA retention. Scatterplots showing the relationship between regional FAZA
retention (relative to muscle) and expression levels of the three HIF-1a regulated genes CA9, GLUT1 and LOX in 2 representative fragmented
FaDudd xenograft tumors. Each dot represents matching values for a single tumor fragment.
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Figure 2 Relative expression of mRNA levels as a function of FAZA retention. Scatterplots showing the relationship between regional FAZA
retention (relative to muscle) and expression levels of the three HIF-1a regulated genes CA9, GLUT1 and LOX in 2 representative fragmented
murine SCCVII tumors. Each dot represents matching values for a single tumor fragment.
Table 1 Summary of Pearson regression coefficients (R) and P values when comparing relative gene expression and
relative FAZA retention in small tumor fragments obtained from 4 human FaDudd tumors and 4 murine SCCVII tumors
FaDudd CA9 GLUT1 LDH GAPDH LOX ATF4
RPRPRPRPR P RP
A 0.77 ≈10
-4 0.85 3×10
-6 0.72 < 10
-3 0.17 0.48 0.77 < 10
-3 -0.65 0.003
B 0.84 5×10
-6 0.89 < 10
-6 0.63 0.003 0.67 0.001 0.86 10
-6 -0.73 < 10
-3
C 0.48 0.04 0.51 0.02 0.62 0.004 0.33 0.17 0.73 < 10
-3 -0.33 0.17
D 0.68 10
-3 0.75 ≈10
-3 0.73 < 10
-3 -0.1 0.69 0.75 < 10
-3 -0.54 0.02
Mean 0.69 0.75 0.67 0.18 0.78 -0.56
Pooled 0.58 < 10
-7 0.74 < 10
-14 0.52 < 10
-6 0.13 0.24 0.76 < 10
-15 -0.45 < 10
-4
SCCVII CA9 GLUT1 LDH GAPDH LOX ATF4
RPRPRPRPR P RP
A 0.92 < 10
-4 0.94 < 10
-4 0.82 0.002 0.89 < 10
-3 -0.54 0.08 0.70 0.02
B 0.89 < 10
-6 0.76 < 10
-3 0.50 0.03 0.80 < 10
-4 -0.48 0.03 0.49 0.04
C 0.60 0.005 0.60 0.005 0.43 0.06 0.53 0.02 -0.35 0.13 0.08 0.7
D 0.70 < 10
-3 0.47 0.03 -0.10 0.67 0.16 0.51 -0.30 0.20 0.36 0.1
Mean 0.78 0.69 0.41 0.59 -0.42 0.41
Pooled 0.65 < 10
-9 0.64 < 10
-8 0.24 0.04 0.56 < 10
-6 -0.38 0.001 0.39 < 10
-3
Analysis was performed on a per-tumor basis (A, B, C and D). Similar data analysis was also performed after data were pooled, i.e., for each gene the relative
gene expression for all fragments for a given tumor type was plotted as function of relative FAZA content followed by regression analysis.
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Page 4 of 9significant in two out of four tumors and when all data
were pooled (Figure 4 Table 1). In contrast a significant
inverse correlation between relative ATF4 mRNA and
FAZA was observed in three out of four FaDudd tumors
and when data were pooled (Figure 3 Table 1).
Discussion
Pre- or during-treatment characterization of tumor
hypoxia, which plays a major role in treatment failure
and disease progression, may allow more effective indivi-
dualized and modifiable therapy. However, due to meth-
odological and interpretational challenges, inadequate
facilities, or huge costs, several of the current available
imaging techniques are still not in routine use. Since
analysis of tumor biopsies is inexpensive and widely
used in diagnosis, indirect assessment of the tumor
microenvironment from genetic analysis in the same
biopsies is clinically attractive if a set of reliable markers
can be identified. Prognostic accuracy may be further
increased by including other molecular markers with
proven prognostic value (e.g., markers of energy meta-
bolism, cell cycle regulation, metastatic potential, or
stem cell characteristics).
Several studies have identified possible mRNA or pro-
tein hypoxia biomarkers based on in vitro cell culture
studies, with special focus on genes that are under the
control of HIF-1a [16]. However, the confounding influ-
ence of other tumor microenvironmental abnormalities
like low glucose and/or low pH on HIF-1a target genes
[17-20] or non-hypoxic HIF-1a activation by abnormal
signalling or mutations [21,22] may be responsible for
some of the spatial discrepancy observed between inject-
able hypoxia markers (e.g., pimonidazole) and O2-
responsive gene protein products (reviewed in [9,10,23]).
Accordingly, among the numerous candidate genes
identified from cell culture experiments it is mandatory
to identify those with a primarily hypoxia-driven gene
expression (high specificity) and with high-fold hypoxic
induction (high sensitivity) also in vivo.
Although proteins are the primary effectors of biologi-
cal function, mRNAs are easier to detect and quantify,
and thus more attractive as clinical biomarkers. In situ
hybridization with RNA probes allows a spatial compari-
son between selected mRNA’s and exogenous hypoxia
probes [24,25]. However, the technique is not quantita-
tive and therefore a clinically useful relationship between
fold-induction of selected hypoxia-responsive genes and
extent of hypoxia cannot be defined. In the present study
we have developed a method that by comparing PET
hypoxia tracer retention and gene expression profiles in
LDH  GAPDH   ATF4 
    
  Relative FAZA retention (tumor-to-muscle)
02468 1 0
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
4
5
6
7
8
9
10
R=0.63; p=0.003
Relative FAZA retention (tumor-to-muscle)
02468 1 0
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
16
17
18
19
20
21
22
23
24
R=0.67; p=0.001 
Relative FAZA retention (tumor-to-muscle)
02468 1 0
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
1.6
1.7
1.8
1.9
2.0
2.1
2.2
2.3
2.4
R=-0.73; p=0.0004 
Relative FAZA retention (tumor-to-muscle)
02468 1 0
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
5
6
7
8
9
10
11
12
R=0.62; p=0.004
Relative FAZA retention (tumor-to-muscle)
02468 1 0
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
18
20
22
24
26
28
R=0.33; p=0.17 
Relative FAZA retention (tumor-to-muscle)
02468 1 0
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
R=-0.33; p=0.17 
B 
C 
Figure 3 Relative expression of mRNA levels as a function of FAZA retention. Scatterplots showing the relationship between regional FAZA
retention (relative to muscle) and expression levels of the two HIF-1a regulated genes LDH and GAPDH and the non-HIF-1a regulated gene
ATF4 in 2 representative fragmented FaDudd xenograft tumors. Each dot represents matching values for a single tumor fragment.
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Page 5 of 9small tumor fragments allows easy identification of in
vivo hypoxia-responsive genes and objective ranking of
these according to hypoxia-specificity. Multiple pair-wise
measurements of gene expression profiles and hypoxia in
individual tumors are superior to whole tumor analysis
since the required number of tumors is reduced and,
more importantly, volumetric downscaling increases con-
clusiveness on true hypoxia-specificity. Furthermore,
variability of global-tumor hypoxic fraction will be
reduced compared to variability in tumor fragments mak-
ing it less likely to identify hypoxia-responsive genes in a
study that relies on bulk tissue profiling of whole tumors.
Fragmentation of tumors resulted in tissue fragments
weighing from 10 to 60 mg with 4 to 6-fold differences in
specific radioactivity in SCCVII tumors and up to 13 fold
in FaDudd tumors; much higher than the intertumor
variability observed when assessing global tumor tracer
retention in the same tumor models [12,26]. Indeed, the
relatively weak correlations observed in the FADudd
tumor C (Figure 1) may be specifically linked to reduced
fragment-to-fragment variability in relative FAZA con-
tent in that particular tumor. Fragmentation into even
smaller tissue segments may, therefore, further increase
the strength of this analysis, but the accuracy of the
determination of the mass of individual fragments and
the need for sufficient mRNA sets a lower size limit of
~5 mg tissue.
Our technique also depends on the ability of FAZA to
accurately quantify relevant hypoxia. In general, a per-
fect match is not expected even between the induction
of an ideal (i.e., strictly pO2 regulated) hypoxia biomar-
ker and relative FAZA retention. First, Km (pO2 for half-
maximal tracer binding/gene induction) for nitroimida-
zole-based compounds is lower than for HIF-1a regu-
lated genes [18,19] and second, the induction levels of
HIF-1a regulated genes plateaus below ~7.5 mmHg
[18,19] whereas the uptake of nitroimidazoles increases
dramatically when near-anoxic conditions are
approached [27,28]. Nonetheless, such differences
should not affect the ranking of genes according to
hypoxia-specificity. In addition, it is well known that
slow tracer distribution may compromise the quantita-
tive accuracy of PET generated hypoxia-maps. Specifi-
cally, necrosis contains less tracer than viable well-
oxygenated reference tissue (i.e., background) which
weakens the correlation between mean tracer signal
intensity and density of hypoxic cells in partly necrotic
tumor regions [29]. However, in two previous studies
comparing FAZA autoradiography and pimonidazole
immunohistochemistry in a mouse tumor model we
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Figure 4 Relative expression of mRNA levels as a function of FAZA retention. Scatterplots showing the relationship between regional FAZA
retention (relative to muscle) and expression levels of the two HIF-1a regulated genes LDH and GAPDH and the non-HIF-1a regulated gene
ATF4 in 2 representative fragmented murine SCCVII tumors. Each dot represents matching values for a single tumor fragment.
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Page 6 of 9have shown that FAZA 3 to 4 h post-injection provides
a highly accurate estimate of the regional number of
hypoxic cells (pO2 < 10 mmHg) even in areas with
hypoxic cells and necrosis intermixed [12,13]. This is
linked to much more effective washout of unbound
(contaminating) tracer at late time points in small ani-
mals than in patients, which maximize the tracer signal
difference between hypoxic and well-oxygenated cells
and minimize the difference between necrotic and well-
oxygenated cells.
In contrast, and more importantly, in two tissue frag-
ments with the same absolute number of hypoxic cells
(and thus comparable FAZA signal) but variable content
of necrotic tissue the number of hypoxic cells relative to
the total number of viable cells will differ. Inclusion of
such partly necrotic fragments would result in dispropor-
tionate high expression levels of hypoxia-responsive
genes, which would appear as outliers above the regres-
sion line in the scattergrams. Inspection of regression
lines suggest that this is not a significant problem,
although the statistically identified outlier (residual >3
standard deviations above mean) in the murine tumor C
(Figure 2) and another murine tumor (not graphed) may
be linked to this problem. Removal of the single outlier
in Figure 2 increases the regression coefficients substan-
tially to 0.81 and 0.79 for CA9 and GLUT-1, respectively.
Transient changes in blood flow, which is common in
solid tumors, may hide a real link between endogenous
and exogenous hypoxia markers. Specifically, since oxy-
genation-driven increases or decreases in mRNA tran-
script levels may take hours (e.g., [19,20]) high levels of
hypoxia-induced mRNA transcripts may still be present
in recently reoxygenated areas (i.e., low FAZA retention)
and newly developed tracer-retaining hypoxic areas may
present with low levels of hypoxia-induced mRNA tran-
scripts. Although the confounding factors discussed
above may weaken a possible linkage between hypoxia
and expression level of putative hypoxia-responsive
genes, they are highly unlikely to affect the ranking of
genes according to hypoxia-specificity or sensitivity.
Our study confirms that two classical markers of
hypoxia, CA9 and GLUT1, also display high hypoxia-
specificity in vivo in FaDudd tumors as evidenced by
highly significant correlations between local FAZA
retention and relative gene induction in all tumors (Fig-
u r e1T a b l e1 ) .A l s ot h ee x p r e s s i o no fL O Xw h i c hh a s
been shown to play a crucial role in hypoxia-induced
metastasis [30] was strongly linked to regional hypoxia
in FaDudd ( F i g u r e1T a b l e1 ) .Ah i g h l ys i g n i f i c a n ta s s o -
ciation between LDH expression level and hypoxia was
also observed, but for a given change in relative FAZA
retention the change in LDH expression level (a reason-
ably estimate of sensitivity as opposed to specificity) is
lower than for CA9, GLUT1 and LOX, making it less
ideal as an in vivo hypoxia biomarker (compare Figure 1
and 3). Reduced in vivo sensitivity of LDH is in accor-
dance with in vitro data from our laboratory showing
that the hypoxia-induced change in induction of HIF-
1a-regulated genes (i.e., hypoxia sensitivity) varies sub-
stantially, with the order of fold-induction as follows
CA9≥LOX>GLUT1 > LDH in FaDudd cells. The lack of
difference in sensitivity between CA9, GLUT1 and LOX
in the present study was not expected based on in vitro
data, but may be linked to a differential influence of
other deviant microenvironmental factors on HIF-1a
regulated genes. For example, it has been shown that
glucose-deprivation stimulates the expression of GLUT1
in myocytes and fibroblasts [31] and tumor cells [32]
and that glucose deprivation and hypoxia has an additive
effect on GLUT1 expression [33]. In contrast, the
expression of CA9 protein (no available mRNA data) is
prevented in HT1080 and FaDu tumor cells at 0.55 mM
glucose [16]. Since glucose deprivation and hypoxia is
likely to coexist, the apparent superiority of CA9
observed in vitro may not be present in vivo.
The relationship between relative CA9, GLUT1 and
LDH expression and FAZA retention in SCCVII tumors
was very similar to the human tumor xenograft. Intrigu-
ingly, however, in SCCVII tumors LOX expression was
uncorrelated or even weakly inversely correlated to tra-
cer retention (Figure 2 Table 1), possibly suggesting a
fundamental species difference in the regulation of
LOX. As this finding was unexpected, the validity of the
results in the murine tumor was confirmed by a differ-
ent LOX qPCR assay.
GAPDH has been used as a housekeeping reference
gene in numerous studies. However, GAPDH is under
the control of HIF-1a [34] and is part of the molecular
manifestation of the Pasteur effect [35] and it is surpris-
ing that GAPDH has been extensively used as a refer-
ence gene in studies involving lowered pO2 [36,37]. In
our hands, GAPDH has consistently been shown to be
induced by hypoxia in vitro (unpublished), and Zhong
and Simons [38] reached the same conclusion in a study
on a diverse selection of tumor and non-transformed
cell lines. In contrast, Said and colleagues [39] reported
that GAPDH mRNA was insensitive to lowered pO2 in
glioblastoma-derived tumor cells and these findings
were later confirmed in other cell lines [40]. The reason
for this fundamental inter-study discrepancy is unclear,
but considering the number of cell lines tested metho-
dological differences should be considered first. In the
present study a weak, but in some tumors significant,
correlation between FAZA retention and GAPDH
expression was observed in both the human and murine
tumor model (Figure 3 and 4, Table 1), suggesting that
GAPDH is neither an appropriate reference gene nor an
ideal hypoxia marker in vivo.
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[ 4 1 ]a n dn o n - H I Fr e g u l a t e dp O 2 responsive genes may
also be useful as hypoxia biomarkers, especially if the
pO2 level of gene induction is lower than for HIF-1a
target genes allowing a sub-population of severely
hypoxic cells to be identified and quantified. ATF4, part
of the unfolded protein response which is involved in
the adaptation of cells to severe hypoxia/anoxia, was
shown to be up-regulated by hypoxia at the level of
mRNA in rat fibroblasts [15]. However, in the human
breast cancer cell line MDA-MB 435 ATF4 mRNA
levels were unaffected by pO2 whereas protein levels
were highly elevated during near-anoxic conditions,
strongly suggesting that regulation is mainly at the level
of translational efficiency [42]. Our in vivo results
revealed a weak, albeit in some tumors significant, posi-
tive (SCCVII, Figure 4 and Table 1) or negative (FaDudd,
Figure 3 and Table 1) correlation between ATF4 mRNA
transcript levels and FAZA retention, suggesting that
ATF4 is not a reliable non-HIF-1a regulated marker of
severe hypoxia at the level of mRNA.
Conclusions
We have developed a technique which allows a quanti-
tative comparison of hypoxic extent and relative gene
expression. A strong positive correlation between regio-
nal CA9, LOX and GLUT1 mRNA transcript levels and
FAZA retention was revealed in a human tumor model
suggesting that these genes display high hypoxia-specificity
in vivo and are superior to LDH and GAPDH. Inclusion of
several xenograft tumor models may allow us to identify
robust in vivo hypoxia-specific tumor-type-independent
biomarkers and construct clinically useful calibration
curves that define the relationship between biopsy
gene expression signatures and extent of hypoxia. The
fragmentation technique may also be useful for estab-
lishing correlations between other labelled tracers and
molecular changes (e.g., FLT and Ki-67, FDG and
GLUT1/hexokinase).
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